Rare pulmonary disease and orphan drugs: a path to the future

Sergio Harari; Yochai Adir; Marc Humbert

doi:10.1183/16000617.0115-2019

Rare pulmonary disease and orphan drugs: a path to the future

Eur Respir Rev. 2019 Oct 1;28(153):190115. doi: 10.1183/16000617.0115-2019. Print 2019 Sep 30.

Authors

Sergio Harari¹, Yochai Adir², Marc Humbert^{3

4

5}

Affiliations

¹ U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria, Servizio di Fisiopatologia Respiratoria e Emodinamica Polmonare, Ospedale San Giuseppe, MultiMedica IRCCS, Milan, Italy sergio@sergioharari.it.
² Pulmonary Division, Lady Davis Carmel Medical Center, Faculty of Medicine, The Technion Institute of Technology, Haifa, Israel.
³ Service de Pneumologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France.
⁴ INSERM UMR S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France.
⁵ Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.

Abstract

The interest in rare diseases is growing. The progress in this field has been made possible by a coordinated action between respiratory researchers, health authorities and patients associations. http://bit.ly/2kIurPH

Publication types

Editorial
Introductory Journal Article

MeSH terms

Animals
Congresses as Topic
Humans
Lung Diseases / drug therapy*
Orphan Drug Production*
Rare Diseases / drug therapy*